Ghayour-Mobarhan M, Lamb D J, Vaidya N, Livingstone C, Wang T, Ferns G A A
Centre for Clinical Science and Measurement, School of Biomedical and Molecular Science, University of Surrey, Guildford, Surrey, UK.
Angiology. 2005 Jan-Feb;56(1):61-8. doi: 10.1177/000331970505600108.
Antibody titers to heat shock protein (Hsp)-60 and -65 are positively related to risk of vascular disease and cardiovascular endpoints. There are few data on the factors that regulate the levels of these antibodies. It is known that the statins have antiinflammatory and immunoregulatory properties. The authors examined the effects of 2 statins, simvastatin (Zocor) and atorvastatin (Lipitor) on antibody titers to Hsp-60, -65, and -70 in a group of dyslipidemic patients. Twenty patients attending a lipid clinic, and previously not receiving lipid-lowering treatment, were treated with 10 mg of simvastatin (n = 11) or atorvastatin (n = 9) for 4 months. An additional 14 patients were recruited from the same clinic at the same hospital as a control group. The medication of these latter patients was unaltered for 4 months and the same parameters were measured as for the statin group. Antibody titers to Hsp-60, -65, and -70 were measured by enzyme-linked immunosorbent assay and lipoprotein profile and highly sensitive serum C-reactive protein (CRP) were measured by routine methods before and after treatment. Pretreatment and posttreatment data were compared by paired t or Mann-Whitney tests. Overall statin treatment was associated with a significant reduction in median antibody titers to Hsp-60 (17.2%, p = 0.03), Hsp-65 (15.9%, p = 0.003) and Hsp-70 (8.3%, p = 0.006), but not in control patients. Both statins caused a reduction in median serum CRP concentrations (45% overall, p < 0.05), but significant changes were not observed in the control patients. The effects on Hsp antibody titers were not related to changes in serum CRP concentrations (p > 0.05). However, there was a significant correlation between changes in antibody titers to Hsp-60 vs Hsp-65 (p < 0.01), Hsp-60 vs Hsp-70 (p < 0.05), and Hsp-65 vs Hsp-70 (p < 0.001). Statin treatment was associated with a reduction in antibody titers to Hsp-60, -65, and -70. This reduction is not fully explained by the antiinflammatory effects of the statins but may be due to their other immunomodulatory properties.
针对热休克蛋白（Hsp）-60和-65的抗体滴度与血管疾病风险及心血管终点呈正相关。关于调节这些抗体水平的因素的数据较少。已知他汀类药物具有抗炎和免疫调节特性。作者研究了两种他汀类药物，辛伐他汀（舒降之）和阿托伐他汀（立普妥）对一组血脂异常患者体内Hsp-60、-65和-70抗体滴度的影响。20名在血脂门诊就诊且此前未接受过降脂治疗的患者，分别接受10毫克辛伐他汀（n = 11）或阿托伐他汀（n = 9）治疗4个月。另外从同一家医院的同一门诊招募了14名患者作为对照组。后一组患者的用药在4个月内保持不变，并测量与他汀类药物组相同的参数。治疗前后通过酶联免疫吸附测定法测量Hsp-60、-65和-70的抗体滴度，通过常规方法测量脂蛋白谱和高敏血清C反应蛋白（CRP）。治疗前和治疗后的数据通过配对t检验或曼-惠特尼检验进行比较。总体而言，他汀类药物治疗与Hsp-60（17.2%，p = 0.03）、Hsp-65（15.9%，p = 0.003）和Hsp-70（8.3%，p = 0.006）的中位抗体滴度显著降低相关，但对照组患者未出现这种情况。两种他汀类药物均导致中位血清CRP浓度降低（总体降低45%，p < 0.05），但对照组患者未观察到显著变化。对Hsp抗体滴度的影响与血清CRP浓度的变化无关（p > 0.05）。然而，Hsp-60与Hsp-65（p < 0.01）、Hsp-60与Hsp-70（p < 0.05）以及Hsp-65与Hsp-70（p < 0.001）的抗体滴度变化之间存在显著相关性。他汀类药物治疗与Hsp-60、-65和-70的抗体滴度降低相关。这种降低不能完全由他汀类药物的抗炎作用来解释，可能是由于它们的其他免疫调节特性。
Zotero 插件